{"id":"NCT00307164","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy","officialTitle":"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-09","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-03-27","resultsPosted":"2011-10-04","lastUpdate":"2021-11-04"},"enrollment":167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections","Lipoatrophy"],"interventions":[{"type":"DRUG","name":"NucleomaxX","otherNames":[]},{"type":"DRUG","name":"NucleomaxX placebo","otherNames":[]}],"arms":[{"label":"NucleomaxX","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV infected individuals on stable ART with lipoatrophy.","primaryOutcome":{"measure":"Change in Limb Fat (g) From Baseline","timeFrame":"Baseline and Week 48","effectByArm":[{"arm":"NucleomaxX","deltaMin":74,"sd":null},{"arm":"Placebo","deltaMin":110,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.64"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":30,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["14640397","16120376","12799554","16152713","20827170"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":83},"commonTop":["Blood cholesterol abnormal","Neuropathy peripheral","Blood glucose abnormal","Low density lipoprotein abnormal","Blood creatine phosphokinase increased"]}}